Replies to post #101170 on Biotech Values

[oc631]

Very strange. Almost seems to raise a red flag on the data.

[DewDiligence]

VRTX—Strange (in the sense that it is opposed to what I'd expect) that patients in the shorter treatment arm had higher SVR rate but higher relapse rate than the longer 48 weeks arm.

The higher SVR rate in the 24-week arm on an ITT basis is explained by fewer dropouts compared to the 48-week arm, which is exactly what one would expect.